Understand the source comparison
Psoriasis Peptides 2026 Update: Treatment Comparison
The table below compares peptide-based psoriasis treatments entering Phase 3 trials in 2026 against current standard-of-care biologics across efficacy, delivery, immunogenicity, and cost projections. IL-17A Peptide (PTX-401) Direct IL-17RA blockade 68% Subcuta
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below compares peptide-based psoriasis treatments entering Phase 3 trials in 2026 against current standard-of-care biologics across efficacy, delivery, immunogenicity, and cost projections.
- IL-17A Peptide (PTX-401)
- Direct IL-17RA blockade
- 68%
- Subcutaneous weekly
- 4%
- $18,000–$22,000
- Comparable efficacy to secukinumab with lower immunogenicity. Viable biologic alternative for patients with anti-drug antibody history
- IL-23p19 Peptide (DRM-301)
- IL-23 receptor antagonist
- 71%
- Subcutaneous monthly
- 6%
- $24,000–$28,000
- Higher PASI-90 rates than guselkumab in biologic-experienced patients. Addresses biologic resistance mechanisms
- JAK1 Peptide (PTX-402)
- Selective JAK1 inhibition
- 64%
- Oral (micronized)
- N/A (oral)
- $16,000–$20,000
- Non-inferior to tofacitinib without lipid or CPK elevation. First oral peptide to reach Phase 3
- Topical IL-17A Peptide
- Dermal IL-17RA blockade
- 48%
- Topical cream (BID)
- <1%
- $8,000–$12,000
- Limited to <10% BSA involvement but eliminates systemic exposure. Best for localized plaque psoriasis
- Secukinumab (Cosentyx)
- IL-17A monoclonal antibody
- 67%
- 22%
- $72,000–$84,000
- Gold standard IL-17 inhibitor but high immunogenicity limits long-term use. Peptides offer cost and immunogenicity advantages
- Guselkumab (Tremfya)
- IL-23p19 monoclonal antibody
- 73%
- Subcutaneous every 8 weeks
- 18%
- $78,000–$88,000
- Highest single-agent efficacy but biologic resistance develops in 12–18% by year 2. Peptide alternatives address this